Abstract
BACKGROUND: The role of body fat on metabolic complications remains poorly understood in young people living with perinatally acquired HIV (YPHIV). OBJECTIVE: Our objective was to assess the association of changes in adiposity over 2 years with metabolic outcomes in YPHIV. METHODS: The PHACS Adolescent Master Protocol (AMP) study enrolled YPHIV from 2007 to 2009 across 15 US sites, including Puerto Rico. We included YPHIV aged 7-19 years with body composition data assessed by whole-body dual-energy X-ray absorptiometry (DXA) at baseline and 2 years later. Metabolic outcomes included homeostatic model assessment of insulin resistance (HOMA-IR) and non-high-density lipoprotein cholesterol (non-HDL-C). We fitted linear regression models to assess the association of increase in body fat over 2 years with metabolic outcomes at years 2 and 3. RESULTS: In all, 232 participants had a second DXA and either HOMA-IR or non-HDL-C measured at year 2. Participant characteristics at the first DXA were: age 12 years (9-14) [median (Q1-Q3)], 69% Black, and median CD4 count 714 cells/μL; 70% with HIV RNA <400 copies ml. in adjusted analyses for every 1% increase in body fat from baseline to year 2, homa-ir was higher by 1.03-fold at year 3 (95% ci: 1.00, 1.05). we observed that for every 1% increase in body fat from baseline to year 2, non-hdl-c was 0.72 mg dl higher at year 2 (95% ci: -0.04-1.49) and 0.81 mg dl higher at year 3 (95% ci: -0.05-1.66). conclusions: increases in adiposity over time may lead to downstream decreased insulin sensitivity and dyslipidaemia in yphiv.>
